Thursday, October 30, 2025 10/30/2025

Innovative Pain and Symptom Management Program for Children with Cancer

Award Number: R01CA222012
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2018
PERIOD OF PERFORMANCE END DATE: 06/30/2025

Group Awards By:

View Award Description

Innovative Pain and Symptom Management Program for Children with Cancer - Every year over 12,000 children will be diagnosed with cancer in the United States and distressing symptoms, such as pain, fatigue, and nausea, are experienced by the majority of these children across all cancer diagnoses. Suboptimal pain and symptom management has the potential for both immediate and long-term effects on children’s physical, social, and emotional functioning. The transition to outpatient care has resulted in a lack of systematic symptom assessment in children undergoing cancer treatment, which results in limited data for healthcare providers regarding children’s symptom experience in the home setting. In addition, current programs targeting pain in children in the home setting are largely limited to assessment tools and do not use patient-reported outcomes or capitalize on the ability of technology to deliver evidence-based pain management skills. Based upon this gap in the literature, we developed a web-based pain and symptom management intervention (Pain Buddy) that incorporates validated patient-reported measures of pain and symptoms in children with cancer, uses an electronic server to deliver child-reported symptom data in real time to healthcare providers, incorporates symptom alert algorithms to notify providers when a child has reported clinically significant symptoms, and teaches children empirically-supported cognitive and behavioral skills for pain management. A small pilot trial successfully demonstrated positive effects of Pain Buddy on pain severity in children undergoing primarily outpatient cancer treatment. The proposed randomized trial of two children’s cancer centers will examine the efficacy of Pain Buddy on decreasing symptom severity and improving quality of life in children with cancer. The primary aim of the study is to determine if Pain Buddy is more effective than attention control in reducing pain severity among children ages 8-18 years old undergoing outpatient cancer treatment. Secondary aims of the study are to: 1) Examine the impact of Pain Buddy on symptom-related distress, health-related quality of life, child functional status, and child and parent satisfaction with treatment experience; and 2) Identify baseline characteristics of children (anxiety, pain catastrophizing) and parents (stress, attitudes regarding analgesic use for children) that may moderate/mediate treatment outcomes. This project paves the way to establish effectiveness of Pain Buddy and ultimately transform care to improve the quality of life of tens of thousands of children suffering from cancer each year.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Cancer Treatment Research	000	5	10/31/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $630,686 )
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	000	5	8/12/2022	NON-COMPETING CONTINUATION	$604,757
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	001	5	8/24/2022	NON-COMPETING CONTINUATION	$0
2022	2022	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	002	5	8/24/2022	SUPPLEMENT FOR EXPANSION	$25,929
														Subtotal = $630,686

Issue Date FY: 2021 ( Subtotal = $639,838 )
2021	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	001	4	6/22/2021	SUPPLEMENT FOR EXPANSION	$67,161
2021	2021	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	000	4	6/17/2021	NON-COMPETING CONTINUATION	$572,677
														Subtotal = $639,838

Issue Date FY: 2020 ( Subtotal = $641,175 )
2020	2020	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	000	3	6/29/2020	NON-COMPETING CONTINUATION	$641,175
														Subtotal = $641,175

Issue Date FY: 2019 ( Subtotal = $640,544 )
2019	2019	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	000	2	7/24/2019	NON-COMPETING CONTINUATION	$640,544
														Subtotal = $640,544

Issue Date FY: 2018 ( Subtotal = $716,535 )
2018	2018	UNIVERSITY OF CALIFORNIA, IRVINE	141 INNOVATION DR STE 250	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	000	1	5/10/2018	NEW	$716,535
														Subtotal = $716,535

Grand Total All Awards = $3,268,778

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Innovative Pain and Symptom Management Program for Children with Cancer

Award Number: R01CA222012

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2018

PERIOD OF PERFORMANCE END DATE: 06/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer